Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Intravitreal bevacizumab for juxtafoveal choroidal neovascularization secondary to multifocal choroiditis
Retina, Volume 33, No. 5, Year 2013
Notification
URL copied to clipboard!
Description
PURPOSE: To assess the effects of intravitreal bevacizumab injections in the treatment of juxtafoveal choroidal neovascularization associated with multifocal choroiditis. METHODS: Prospective interventional case series. Fourteen patients (14 eyes) affected by juxtafoveal choroidal neovascularization secondary to multifocal choroiditis were examined. All patients underwent a complete ophthalmologic examination, including measurement of best-corrected visual acuity using Early Treatment Diabetic Retinopathy Study charts, optical coherence tomography, and fluorescein angiography. The protocol treatment included a first injection, followed by repeated intravitreal bevacizumab injections over a 12-month follow-up period on the basis of optical coherence tomography parameters and angiographic features. RESULTS: Mean best-corrected visual acuity changed from 0.41 logarithm of the minimum angle of resolution (approximately corresponding to 20/51 Snellen equivalent), at baseline, to 0.16 ± 0.13 logarithm of the minimum angle of resolution (approximately corresponding to 20/28 Snellen equivalent), at the 12-month examination (P < 0.002). A functional improvement of at least 3 Early Treatment Diabetic Retinopathy Study lines was achieved by 6 eyes (43%) at the 12-month examination. Mean central macular thickness at baseline was 318 μm, reducing to 239 μm at the 12-month examination (P < 0.001). No eye showed choroidal neovascularization extension to the fovea. CONCLUSION: Intravitreal bevacizumab is a beneficial treatment for juxtafoveal choroidal neovascularization associated with multifocal choroiditis. Further studies are warranted to confirm these preliminary results. Copyright © by Ophthalmic communications Society, Inc.
Authors & Co-Authors
Battaglia Parodi, Maurizio
Italy, Milan
Università Vita-salute San Raffaele
Iacono, P.
Italy, Rome
Irccs Fondazione G.b. Bietti Per lo Studio e la Ricerca in Oftalmologia - Onlus
Mansour, Ahmad M.
Lebanon, Beirut
American University of Beirut
Benedetto, Umberto De
Italy, Milan
Università Vita-salute San Raffaele
Knutsson, K. A.
Italy, Milan
Università Vita-salute San Raffaele
Bandello, Francesco Maria
Italy, Milan
Università Vita-salute San Raffaele
Ziemssen, Focke
Germany, Tubingen
Eberhard Karls Universität Tübingen
Ness, Thomas
Germany, Freiburg Im Breisgau
Universitätsklinikum Freiburg
Dodwell, David
United States, Springfield
Siu School of Medicine
Statistics
Citations: 14
Authors: 9
Affiliations: 6
Identifiers
Doi:
10.1097/IAE.0b013e318275397c
ISSN:
0275004X
e-ISSN:
15392864
Research Areas
Health System And Policy
Study Design
Cohort Study